The Wellness Lighting Market Has Three Layers. Only One Is Investable.

A press release published today carries the code "CTK-6233" in its title. If you've ever seen a stock ticker with a dash and number like that, you might have paused to look up the chart.

There is no such stock. CTK-6233 is a case file number from InventHelp, a Pittsburgh-based invention service. The "announcement" is about a product called SUN ORB, a wellness-oriented light from an inventor in Norman, Oklahoma, that the inventor hopes will bring the benefits of natural sunlight indoors. It has no prototype. No revenue. No company. It is an idea looking for a buyer, posted publicly because the inventor paid InventHelp to put it there.

InventHelp charges between $800 and $10,000 in service fees. The company makes its money from inventors, not from the commercial success of their ideas. The press release is the product.

This is not the interesting part. The interesting part is what happens when you follow the category the idea is targeting — wellness or "circadian" lighting — into the actual market. The human-centric lighting market was worth $5.9 billion in 2026 and is projected to more than triple by 2033. That is the sort of growth number that makes any business plan glow. But between the invention pitch and the TAM slide, there is a real business that already does this at scale, and it is having a very hard time.

Signify — formerly Philips Lighting — is the world's largest lighting company and the closest publicly traded play on the wellness lighting trend. Its ADR trades under PHPPY in the U.S. It has a market cap of about $2.1 billion and pays a dividend yield of roughly 8%. That yield is the number that tells you what has happened to the stock.

Signify's Q2 2026 results show a company losing ground. Sales of €1.33 billion were down 3.6% year over year. Adjusted EBITA margin fell from 7.8% to 6.1%. Net income dropped from €57 million a year earlier to €17 million. Management called it a "mixed market environment" and confirmed full-year guidance of 7.5% to 8.5% adjusted EBITA margin. That guidance implies a steep second-half recovery that has not yet shown up in the data.

The consumer segment — the one that matters for wellness lighting — was a particular problem. Connected products sold well to end users, but retailers were pulling back on orders because of inventory adjustments. In the lighting business, when retailers slow their orders, the manufacturer bleeds first.

Now look at the consumer light therapy market on its own. This is the narrow slice where SUN ORB is aiming. You can buy a Verilux HappyLight or a Carex Day-Light lamp today. The Wirecutter reviewed 35 different models recently and picked winners. Verilux, founded 60 years ago, is now owned by Bear Down Brands, a private company. Carex is also private. Neither will give you a stock ticker.

So the wellness lighting market has three layers. At the top, you have the invention service press release — an idea for sale, with no product. In the middle, you have the private consumer brands that already own the shelf space, the reviews, and the repeat buyers. At the bottom, you have the one public company, Signify, which is trying to sell circadian lighting to offices and buildings while its consumer business gets squeezed.

Most people approach this category the wrong way. They see the TAM — $22 billion by 2033 — and assume there's room for the next big wellness lighting brand to break through. But the question is not whether the market is growing. It's whether the structure of the market rewards new entrants or protects the incumbents.

In consumer light therapy, the evidence points to incumbents. The products are differentiated by clinical credibility, brand trust, and reviews. You're buying a lamp that promises to improve your mood and circadian rhythm. That is the kind of purchase where you read other people's experiences before you spend your money. The brand that's been selling for 60 years has a structural advantage over the one that exists as a PDF and a phone number in Norman, Oklahoma.

Signify has a different problem. It's not trying to break into a new category — it already owns the category name in the commercial space. Its circadian lighting products are deployed in offices, schools, and healthcare facilities. But the company is too large and too diversified for this to be the main story. It manufactures everything from conventional bulbs for upstream OEM customers to connected LED systems for smart buildings. The wellness angle is a feature of a portfolio, not the portfolio itself. And the margins are telling you the market is not paying a premium for that feature.

I suspect the real investment question here has nothing to do with SUN ORB or any single invention. It's whether wellness lighting becomes a premium consumer category — where a few brands charge $150 to $300 for a mood lamp and earn repeat customers — or whether it stays what it is: an incremental feature bolted onto the lighting industry's existing cost competition.

The sign will show up in Signify's numbers. If the consumer segment recovers strongly in the second half of 2026 and the connected products business grows meaningfully, then wellness lighting may be earning a real premium. If the consumer business continues to struggle while Signify's overall margins hover in the low single digits, then the "wellness lighting" label is just marketing language for a business selling light at lower prices than it used to.

Before you chase a category because of a growth number, check who's already selling in it. Check whether the growth is coming from new demand or from incumbents slowly stealing share from adjacent categories. And check the public companies to see whether the growth has reached their income statement yet. The TAM doesn't invest itself.